Does Deal With Roche Signal Eleven's Doomed Fate?

Eleven Biotherapeutics Inc. more than doubled in value in early trading on June 13 before closing up 27.8% at $2.39 per share after the company said it licensed EBI-031, its lead development program, to Roche – a move that could signal Eleven's intention to wind down the eye disease-focused company.

Eleven Biotherapeutics Inc. more than doubled in value in early trading on June 13 before closing up 27.8% at $2.39 per share after the company said it licensed EBI-031, its lead development program, to Roche – a move that could signal Eleven's intention to wind down the eye disease-focused company.

Cambridge, Massachusetts-based Eleven was left with no clinical candidates back in January after its topical drug isunakinra (EBI-005) failed in...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip